Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not

European Journal of Clinical Pharmacology

Volumn 62, Issue 9, 2006, Pages 713-720

  Schwabedissen, Cordula Meyer Zu ^a   Mevissen, Vera ^a   Schmitz, Fabian ^a   Woodruff, Seth ^a   Langebartels, Georg ^a   Rau, Thomas ^b   Zerres, Klaus ^a   Hoffmann, Rainer ^a   Ortlepp, Jan R ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CYP2C9; Genetic polymorphism; Phenprocoumon

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; CYTOCHROME P450 2C9; HEPARIN; NEUROLEPTIC AGENT; PHENPROCOUMON; PHOSPHODIESTERASE I; VITAMIN K GROUP; WARFARIN;

ADULT; ARTICLE; BODY FAT; BODY MASS; COMORBIDITY; DIETARY INTAKE; DISEASE MARKER; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FOOD DRUG INTERACTION; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; WAIST HIP RATIO;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OBESITY; PHENPROCOUMON; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; VITAMIN K;

EID: 33747883514     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0158-3     Document Type: Article

References (20)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154):717-719
2. Cannegieter SC, Torn M, Rosendaal FR (1999) Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 245(4):369-374
3. Fihn SD, Gadisseur AA, Pasterkamp E, van der Meer FJ, Breukink-Engbers WG, Geven-Boere LM, van Meegen E, de Vries-Goldschmeding H, Antheunissen- Anneveld I, van't Hoff AR, Harderman D, Smink M, Rosendaal FR (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 90(2):260-266
4. Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30(6):416-444
5. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372(1):16-28
6. Heaf J, Guldager B (1990) Algorithm for short-term prescription of phenprocoumon. Haemostasis 20(1):21-30
7. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698
8. Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM (2003) Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 59(3):213-219
9. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75(3):204-212
10. Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, Schwab M, Gleiter CH, Rane A, Roots I, Brockmoller J (2004) Effects of CYP2C9 polymorphisms on the pharmacokinetics of R-and S-phenprocoumon in healthy volunteers. Pharmacogenetics 14(1):19-26
11. Penning-van Beest FJ, Rosendaal FR, Grobbee DE, van Meegen E, Stricker BH (1999) Course of the international normalized ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol 104 (2):241-245
12. Russmann S, Gohlke-Barwolf C, Jahnchen E, Trenk D, Roskamm H (1997) Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. Eur J Clin Pharmacol 52(1):31-35
13. Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A (2004) Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 76 (5):409-417
14. Trenk D, Althen H, Jahnchen E, Meinertz T, Oie S (1987) Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol 33 (1):49-54
15. Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmoller J, Rane A (2004) Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 34(9):847-859
16. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60(3):173-182
17. van Haeften TW, de Vries J, Sixma JJ (1997) Concordance of phenprocoumon dosage in married couples. BMJ 314 (7091):1386
18. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2004) The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 92(1):61-66
19. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1):27-33
20. Wilkerson WR, Sane DC (2002) Aging and thrombosis. Semin Thromb Hemost 28(6):555-568